Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)

~18 mi. (Breda, Netherlands, +226 more cities)

Amphia Hospital Location Molengracht ( Site 0474)

Prostate Adenocarcinoma

enzalutamide, +1 more drug

hormone therapy, +1 more type

A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)

~18 mi. (Breda, Netherlands, +93 more cities)

Amphia Hospital Location Molengracht ( Site 1912)

Clear Cell Renal Cell Carcinoma

belzutifan, +1 more drug

targeted therapy

A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer

~18 mi. (Breda, Netherlands, +209 more cities)

Amphia Ziekenhuis

ERBB2 Amplification, +1 more biomarker

Breast Carcinoma

ado-trastuzumab emtansine, +1 more drug

targeted therapy

Treatment Strategies in Colorectal Cancer Patients With Initially Unresectable Liver-only Metastases

~18 mi. (Breda, Netherlands, +54 more cities)

Amphia Ziekenhuis

Colorectal Carcinoma

bevacizumab, +6 more drugs

chemotherapy, +1 more type

Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer

~20 mi. (Brasschaat, Belgium, +206 more cities)

Algemeen Ziekenhuis Klina

Non-Squamous Non-Small Cell Lung Carcinoma

nivolumab, +1 more drug

immunotherapy, +1 more type

Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003/LYNK-003)

~20 mi. (Brasschaat, Belgium, +105 more cities)

AZ Klina ( Site 0106)

Colorectal Adenocarcinoma

bevacizumab, +1 more drug

targeted therapy

A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer

~25 mi. (Het Bosch, Netherlands, +184 more cities)

Jeroen Bosch Hospital

RET Fusion

Non-Squamous Non-Small Cell Lung Carcinoma

selpercatinib

targeted therapy

A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies

~28 mi. (Antwerpen, Belgium, +4 more cities)

University Hospital Antwerp

B-Cell Non-Hodgkin Lymphoma, +1 more condition

MCLA-145

immunotherapy

Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)

~30 mi. (Edegem, Belgium, +147 more cities)

UZA University Hospital Antwerp ( Site 0351)

Cervical Adenocarcinoma, +2 more conditions

brachytherapy, +3 more drugs

chemotherapy, +2 more types

Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)

~30 mi. (Edegem, Belgium, +130 more cities)

UZA University Hospital Antwerp ( Site 0105)

Bladder Urothelial Carcinoma

BCG solution, +1 more drug

immunotherapy

Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)

~30 mi. (Edegem, Belgium, +199 more cities)

University Hospital Antwerp (UZA) ( Site 0374)

Hepatocellular Carcinoma

pembrolizumab

immunotherapy

A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)

~30 mi. (Edegem, Belgium, +356 more cities)

Antwerp University Hospital

HER2 Positive

Invasive Breast Carcinoma

fam-trastuzumab deruxtecan

targeted therapy